Who Should Decide If Gene Therapy Is Too Risky, Patients or the FDA? – Seeker
|
Who Should Decide If Gene Therapy Is Too Risky, Patients or the FDA?
Seeker But the US Food and Drug Administration and many other international regulatory bodies have been slow to approve human trials due to the high risks associated with tinkering with a patient's DNA. Liz Parrish thinks that the FDA and the medical … |
